This technology will prove to be extremely valuable in fighting the Multiple Myeloma disease. It has the ability to predict relapse disease potential and patient survival rate.

About

Highlights


Accurate prognosis.
Guides treatment options.
Patent pending.


Multiple Myeloma is a highly prevalent disease accounting for 1-2% of all cancers, with a market size for treatments estimated to grow to $7 billion by 2020. This technology will prove to be extremely valuable in fighting this disease.

Advantages over Current Technologies Include


Ability to predict relapse/refractory disease potential and patient survival rates. Used to guide treatment options.
Potential to serve as a novel disease-specific drug target.


Stage of Development

Broad ranging patent applied for. Seeking co-development partner to advance assay to the market.

Objective

This technology is available for licensing.

 

Purchase a license for full unlimited access to all innovation profiles on LEO

  • Direct connection to thousands of more innovations
  • Access to market Experts and Universities
  • Filter relevant solutions into your own dedicated Network